Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Editorial/Perspectives

  • Editorial/Perspectives
    Uncommon tumors and exceptional therapies: paradox or paradigm?
    Fadi Braiteh and Razelle Kurzrock
    Mol Cancer Ther April 1 2007 6 (4) 1175-1179; DOI:10.1158/1535-7163.MCT-06-0674

Drug Development Series: Review

  • Drug Development Series: Review
    The randomized discontinuation trial: a phase II design to assess growth-inhibitory agents
    Walter M. Stadler
    Mol Cancer Ther April 1 2007 6 (4) 1180-1185; DOI:10.1158/1535-7163.MCT-06-0249

Review

  • Review
    Tumor-stroma interactions in pancreatic ductal adenocarcinoma
    Daruka Mahadevan and Daniel D. Von Hoff
    Mol Cancer Ther April 1 2007 6 (4) 1186-1197; DOI:10.1158/1535-7163.MCT-06-0686

Research Articles: Therapeutics, Targets, and Development

  • Research Articles: Therapeutics, Targets, and Development
    Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues
    Swee Y. Sharp, Chrisostomos Prodromou, Kathy Boxall, Marissa V. Powers, Joanna L. Holmes, Gary Box, Thomas P. Matthews, Kwai-Ming J. Cheung, Andrew Kalusa, Karen James, Angela Hayes, Anthea Hardcastle, Brian Dymock, Paul A. Brough, Xavier Barril, Julie E. Cansfield, Lisa Wright, Allan Surgenor, Nicolas Foloppe, Roderick E. Hubbard, Wynne Aherne, Laurence Pearl, Keith Jones, Edward McDonald, Florence Raynaud, Sue Eccles, Martin Drysdale and Paul Workman
    Mol Cancer Ther April 1 2007 6 (4) 1198-1211; DOI:10.1158/1535-7163.MCT-07-0149

  • Research Articles: Therapeutics, Targets, and Development
    MAP-ing glioma invasion: Mitogen-activated protein kinase kinase 3 and p38 drive glioma invasion and progression and predict patient survival
    Tim Demuth, Linsey B. Reavie, Jessica L. Rennert, Mitsutoshi Nakada, Satoko Nakada, Dominique B. Hoelzinger, Christian E. Beaudry, Amanda N. Henrichs, Eric M. Anderson and Michael E. Berens
    Mol Cancer Ther April 1 2007 6 (4) 1212-1222; DOI:10.1158/1535-7163.MCT-06-0711

  • Research Articles: Therapeutics, Targets, and Development
    Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens
    Lorenzo Daniele, Luigia Macrì, Marina Schena, Diego Dongiovanni, Lisa Bonello, Enrico Armando, Libero Ciuffreda, Oscar Bertetto, Gianni Bussolati and Anna Sapino
    Mol Cancer Ther April 1 2007 6 (4) 1223-1229; DOI:10.1158/1535-7163.MCT-06-0719

  • Research Articles: Therapeutics, Targets, and Development
    Use of fluorescent labeled anti–epidermal growth factor receptor antibody to image head and neck squamous cell carcinoma xenografts
    Eben L. Rosenthal, Brian D. Kulbersh, Teresa King, Tandra R. Chaudhuri and Kurt R. Zinn
    Mol Cancer Ther April 1 2007 6 (4) 1230-1238; DOI:10.1158/1535-7163.MCT-06-0741

  • Research Articles: Therapeutics, Targets, and Development
    H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation
    Brett Ewald, Deepa Sampath and William Plunkett
    Mol Cancer Ther April 1 2007 6 (4) 1239-1248; DOI:10.1158/1535-7163.MCT-06-0633

  • Research Articles: Therapeutics, Targets, and Development
    Activation of a novel ataxia-telangiectasia mutated and Rad3 related/checkpoint kinase 1–dependent prometaphase checkpoint in cancer cells by diallyl trisulfide, a promising cancer chemopreventive constituent of processed garlic
    Anna Herman-Antosiewicz, Silvia D. Stan, Eun-Ryeong Hahm, Dong Xiao and Shivendra V. Singh
    Mol Cancer Ther April 1 2007 6 (4) 1249-1261; DOI:10.1158/1535-7163.MCT-06-0477

  • Research Articles: Therapeutics, Targets, and Development
    Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib
    Peter Pyrko, Adel Kardosh, Yen-Ting Liu, Nathaniel Soriano, Wenyong Xiong, Robert H. Chow, Jasim Uddin, Nicos A. Petasis, Austin K. Mircheff, Robert A. Farley, Stan G. Louie, Thomas C. Chen and Axel H. Schönthal
    Mol Cancer Ther April 1 2007 6 (4) 1262-1275; DOI:10.1158/1535-7163.MCT-06-0629

  • Research Articles: Therapeutics, Targets, and Development
    Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer
    Lan Li, Bilal Ahmed, Kapil Mehta and Razelle Kurzrock
    Mol Cancer Ther April 1 2007 6 (4) 1276-1282; DOI:10.1158/1535-7163.MCT-06-0556

  • Research Articles: Therapeutics, Targets, and Development
    Molecular mechanisms of the chemopreventive effect on hepatocellular carcinoma development in Mdr2 knockout mice
    Mark Katzenellenbogen, Lina Mizrahi, Orit Pappo, Naama Klopstock, Devorah Olam, Hila Barash, Eytan Domany, Eithan Galun and Daniel Goldenberg
    Mol Cancer Ther April 1 2007 6 (4) 1283-1291; DOI:10.1158/1535-7163.MCT-06-0420

  • Research Articles: Therapeutics, Targets, and Development
    Loss of mitochondrial membrane potential is inhibited by bombesin in etoposide-induced apoptosis in PC-3 prostate carcinoma cells
    Mercedes Salido, Juan L. Gonzalez and Jose Vilches
    Mol Cancer Ther April 1 2007 6 (4) 1292-1299; DOI:10.1158/1535-7163.MCT-06-0681

  • Research Articles: Therapeutics, Targets, and Development
    The RET oncogene is a critical component of transcriptional programs associated with retinoic acid–induced differentiation in neuroblastoma
    Orit Oppenheimer, Nai-Kong Cheung and William L. Gerald
    Mol Cancer Ther April 1 2007 6 (4) 1300-1309; DOI:10.1158/1535-7163.MCT-06-0587

  • Research Articles: Therapeutics, Targets, and Development
    Levels of p27kip1 determine Aplidin sensitivity
    Victoria Moneo, Beatriz G. Serelde, Juan F.M. Leal, Carmen Blanco-Aparicio, Ramon Diaz-Uriarte, Miguel Aracil, Juan C. Tercero, José Jimeno and Amancio Carnero
    Mol Cancer Ther April 1 2007 6 (4) 1310-1316; DOI:10.1158/1535-7163.MCT-06-0729

  • Research Articles: Therapeutics, Targets, and Development
    Farnesyl transferase inhibitors impair chromosomal maintenance in cell lines and human tumors by compromising CENP-E and CENP-F function
    Katherine Schafer-Hales, Jon Iaconelli, James P. Snyder, Andrew Prussia, James H. Nettles, Adel El-Naggar, Fadlo R. Khuri, Paraskevi Giannakakou and Adam I. Marcus
    Mol Cancer Ther April 1 2007 6 (4) 1317-1328; DOI:10.1158/1535-7163.MCT-06-0703

  • Research Articles: Therapeutics, Targets, and Development
    Tumor cytotoxicity and endothelial Rac inhibition induced by TNP-470 in anaplastic thyroid cancer
    Dorit Nahari, Ronit Satchi-Fainaro, Ming Chen, Ian Mitchell, Laurie B. Task, Zijuan Liu, Jason Kihneman, Allison B. Carroll, Lance S. Terada and Fiemu E. Nwariaku
    Mol Cancer Ther April 1 2007 6 (4) 1329-1337; DOI:10.1158/1535-7163.MCT-06-0554

  • Research Articles: Therapeutics, Targets, and Development
    Luteolin sensitizes the anticancer effect of cisplatin via c-Jun NH2-terminal kinase–mediated p53 phosphorylation and stabilization
    Ranxin Shi, Qing Huang, Xinqiang Zhu, Yeong-Bing Ong, Bin Zhao, Jia Lu, Choon-Nam Ong and Han-Ming Shen
    Mol Cancer Ther April 1 2007 6 (4) 1338-1347; DOI:10.1158/1535-7163.MCT-06-0638

  • Research Articles: Therapeutics, Targets, and Development
    Identification of a novel inhibitor of urokinase-type plasminogen activator
    Ming Zhu, Vijay M. Gokhale, Lajos Szabo, Ruben M. Munoz, Hyounggee Baek, Sridevi Bashyam, Laurence H. Hurley, Daniel D. Von Hoff and Haiyong Han
    Mol Cancer Ther April 1 2007 6 (4) 1348-1356; DOI:10.1158/1535-7163.MCT-06-0520

  • Research Articles: Therapeutics, Targets, and Development
    Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo
    Ta-Jen Liu, Tiffany LaFortune, Toshiyuki Honda, Osamu Ohmori, Shinji Hatakeyama, Thomas Meyer, Dowdy Jackson, John de Groot and W.K. Alfred Yung
    Mol Cancer Ther April 1 2007 6 (4) 1357-1367; DOI:10.1158/1535-7163.MCT-06-0476

  • Research Articles: Therapeutics, Targets, and Development
    S-phase checkpoints regulate Apo2 ligand/TRAIL and CPT-11–induced apoptosis of prostate cancer cells
    Subrata Ray, Sunitha Shyam, Gail C. Fraizer and Alexandru Almasan
    Mol Cancer Ther April 1 2007 6 (4) 1368-1378; DOI:10.1158/1535-7163.MCT-05-0414

  • Research Articles: Therapeutics, Targets, and Development
    Clofibric acid, a peroxisome proliferator–activated receptor α ligand, inhibits growth of human ovarian cancer
    Yoshihito Yokoyama, Bing Xin, Tatsuhiko Shigeto, Mika Umemoto, Akiko Kasai-Sakamoto, Masayuki Futagami, Shigeki Tsuchida, Fahd Al-Mulla and Hideki Mizunuma
    Mol Cancer Ther April 1 2007 6 (4) 1379-1386; DOI:10.1158/1535-7163.MCT-06-0722

  • Research Articles: Therapeutics, Targets, and Development
    Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1
    Stavroula Baritaki, Sara Huerta-Yepez, Toshiyuki Sakai, Demetrios A. Spandidos and Benjamin Bonavida
    Mol Cancer Ther April 1 2007 6 (4) 1387-1399; DOI:10.1158/1535-7163.MCT-06-0521

  • Research Articles: Therapeutics, Targets, and Development
    Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells
    Sangkil Nam, Ann Williams, Adina Vultur, Alan List, Kapil Bhalla, David Smith, Francis Y. Lee and Richard Jove
    Mol Cancer Ther April 1 2007 6 (4) 1400-1405; DOI:10.1158/1535-7163.MCT-06-0446

  • Research Articles: Therapeutics, Targets, and Development
    Loss of ataxia telangiectasia mutated– and Rad3-related function potentiates the effects of chemotherapeutic drugs on cancer cell survival
    Deborah Wilsker and Fred Bunz
    Mol Cancer Ther April 1 2007 6 (4) 1406-1413; DOI:10.1158/1535-7163.MCT-06-0679

  • Research Articles: Therapeutics, Targets, and Development
    Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer
    Qing Zhang, Neil E. Bhola, Vivian Wai Yan Lui, Doris R. Siwak, Sufi M. Thomas, Christopher T. Gubish, Jill M. Siegfried, Gordon B. Mills, Dong Shin and Jennifer Rubin Grandis
    Mol Cancer Ther April 1 2007 6 (4) 1414-1424; DOI:10.1158/1535-7163.MCT-06-0678

  • Research Articles: Therapeutics, Targets, and Development
    Combined effects of retinoic acid and histone deacetylase inhibitors on human neuroblastoma SH-SY5Y cells
    Maxy De los Santos, Alberto Zambrano and Ana Aranda
    Mol Cancer Ther April 1 2007 6 (4) 1425-1432; DOI:10.1158/1535-7163.MCT-06-0623

  • Research Articles: Therapeutics, Targets, and Development
    1α,25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells
    Moshe Ben-Shoshan, Sharon Amir, Duyen T. Dang, Long H. Dang, Yosef Weisman and Nicola J. Mabjeesh
    Mol Cancer Ther April 1 2007 6 (4) 1433-1439; DOI:10.1158/1535-7163.MCT-06-0677

  • Research Articles: Therapeutics, Targets, and Development
    Inhibition of nuclear factor-κB augments antitumor activity of adenovirus-mediated melanoma differentiation-associated gene-7 against lung cancer cells via mitogen-activated protein kinase kinase kinase 1 activation
    Yasuhisa Oida, Began Gopalan, Ryo Miyahara, Cynthia D. Branch, Paul Chiao, Sunil Chada and Rajagopal Ramesh
    Mol Cancer Ther April 1 2007 6 (4) 1440-1449; DOI:10.1158/1535-7163.MCT-06-0374

  • Research Articles: Therapeutics, Targets, and Development
    Activation of clinically used anthracyclines by the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate
    Suzanne M. Cutts, Lonnie P. Swift, Vinochani Pillay, Robert A. Forrest, Abraham Nudelman, Ada Rephaeli and Don R. Phillips
    Mol Cancer Ther April 1 2007 6 (4) 1450-1459; DOI:10.1158/1535-7163.MCT-06-0551

  • Research Articles: Therapeutics, Targets, and Development
    Novel xenograft model expressing human hepatocyte growth factor shows ligand-dependent growth of c-Met–expressing tumors
    Todd D. Francone, Ron G. Landmann, Chin-Tung Chen, Mark Y. Sun, Eleanor J. Kuntz, Zhaoshi Zeng, Ronald P. Dematteo, Philip B. Paty and Martin R. Weiser
    Mol Cancer Ther April 1 2007 6 (4) 1460-1466; DOI:10.1158/1535-7163.MCT-06-0466

  • Research Articles: Therapeutics, Targets, and Development
    Phospholipid hydroperoxide glutathione peroxidase plays a role in protecting cancer cells from docosahexaenoic acid–induced cytotoxicity
    Wei-Qun Ding and Stuart E. Lind
    Mol Cancer Ther April 1 2007 6 (4) 1467-1474; DOI:10.1158/1535-7163.MCT-06-0608

Back to top
PreviousNext
Molecular Cancer Therapeutics: 6 (4)
April 2007
Volume 6, Issue 4
  • Table of Contents
  • About the Cover

Sign up for alerts

Issue Highlights

  • Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues

Jump to

  • Editorial/Perspectives
  • Drug Development Series: Review
  • Review
  • Research Articles: Therapeutics, Targets, and Development
Advertisement
  • Most Cited
  • Most Read
Loading
  • CD137 Agonist mAb with Reduced Liver Toxicity
  • Truncated BRCA2 Contributes to PARPi Resistance
  • ERPAS to Predict Response to Endocrine Therapy
  • CDK8/19 Inhibitors Enhance NK-Cell–Mediated Cancer Therapy
  • Sialoglycan mAb for Cancer Immunotherapy
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement